<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Franklin D Lowy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Methicillin resistance in <em>Staphylococcus aureus</em> (MRSA) is defined by the Clinical Laboratory Standards Institute (CLSI) as an <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a> minimum inhibitory concentration (MIC) ≥4 mcg/mL [<a href="#rid1">1</a>]. According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), <em>S. aureus</em> with oxacillin MIC values &gt;2 mg/L are mostly methicillin resistant [<a href="#rid2">2</a>].</p><p>Issues related to treatment of skin and soft tissue infections in adults caused by MRSA will be reviewed here.</p><p>General issues related to skin and soft tissue infections are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a>.)</p><p>Other issues related to MRSA are discussed further separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3157.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3166.html" rel="external">"Rapid detection of methicillin-resistant Staphylococcus aureus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p></p><p class="headingAnchor" id="H4203034019"><span class="h1">CLINICAL APPROACH</span><span class="headingEndMark"> — </span>Patients with skin and soft tissue infections known or suspected to be due to MRSA may present with cellulitis, abscess, or both [<a href="#rid3">3-5</a>]. Issues related to evaluation of cellulitis and for presence of abscess are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p>Patients with cellulitis should be managed with antibiotic therapy. A critical part of treatment is source control. Patients with an abscess should undergo incision and drainage, and debrided material should be sent for culture and susceptibility testing [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/6336.html" rel="external">"Techniques for skin abscess drainage"</a>.)</p><p>The role of antibiotic therapy for patients with abscess depends on individual clinical circumstances. (See  <a class="medical medical_review" href="/z/d/html/138447.html" rel="external">"Skin abscesses in adults: Treatment", section on 'Indications for antimicrobial therapy'</a>.)</p><p class="headingAnchor" id="H3718217301"><span class="h1">ANTIBIOTIC SELECTION</span><span class="headingEndMark"> — </span>Empiric coverage for MRSA is generally warranted for treatment of skin and soft tissue infections, given the high community prevalence of MRSA. Clinical and epidemiologic factors alone do not adequately predict the likelihood of MRSA infection  (<a class="graphic graphic_table graphicRef53504" data-inline-graphics="53504" href="/z/d/graphic/53504.html" rel="external">table 1</a>) [<a href="#rid8">8</a>]. Empiric antibiotic therapy with activity against MRSA is particularly important in the following circumstances [<a href="#rid8">8-10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior episode of MRSA infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent infection in the setting of underlying predisposing condition(s)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin and soft tissue infection not associated with purulence, in the setting of inadequate clinical response (within 72 hours) to antibiotic therapy with no activity against MRSA</p><p></p><p>Antibiotic therapy should be tailored to susceptibility data when available. Therapy should preferentially include a narrow spectrum antibiotic. Patients with mild infection (localized involvement with no systemic symptoms) may be treated with oral antibiotic therapy. Treatment with parenteral antibiotic therapy is warranted in the circumstances described below. (See <a class="local">'Oral antibiotic therapy'</a> below and <a class="local">'Parenteral antibiotic therapy'</a> below.)</p><p>Considerations in antibiotic selection include local antibiotic susceptibility profiles and individual patient circumstances, including underlying comorbidities and concurrent medications [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Oral antibiotic therapy</span><span class="headingEndMark"> — </span>Patients with mild infection (localized involvement with no systemic symptoms) due to known or suspected MRSA may be treated with oral antibiotic therapy. Antibiotic dosing is summarized in the table  (<a class="graphic graphic_table graphicRef64178" data-inline-graphics="64178" href="/z/d/graphic/64178.html" rel="external">table 2</a>).</p><p>Oral antibiotic agents of choice include <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX), tetracyclines (such as <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>), or <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> [<a href="#rid4">4,12-15</a>]. In general, the choice between agents is guided by individual clinical circumstances including local antibiotic resistance patterns, allergy history, and concomitant medications.</p><p>The efficacy of <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and TMP-SMX for treatment of uncomplicated skin infection is comparable; in two randomized trials including patients with uncomplicated skin infections, cure rates for clindamycin and TMP-SMX were between 78 and 83 percent [<a href="#rid16">16,17</a>]. Use of the tetracyclines is supported by susceptibility testing and observational and retrospective reports; their efficacy for treatment of skin and soft tissue infections due to MRSA has not been rigorously evaluated or compared in clinical trials [<a href="#rid15">15,18-21</a>].</p><p>In the setting of empiric antibiotic therapy, the efficacy of the above agents against the potential pathogen group A <em>Streptococcus</em> (GAS) should be considered. <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> and TMP-SMX are active against GAS; <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> has uncertain activity [<a href="#rid17">17,22,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a>.)</p><p>Alternative oral agents include oxazolidinones (<a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> and <a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">tedizolid</a>), the fluoroquinolone <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">delafloxacin</a>, and the <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a>; use of these drugs is limited by cost, clinical experience, and adverse drug effects. They should be reserved for patients who do not respond to or cannot tolerate other agents. (See <a class="local">'Alternative agents'</a> below.)</p><p>Careful monitoring of local <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> resistance rates is important; some favor avoiding empiric clindamycin therapy when local MRSA resistance rates to clindamycin exceed 10 to 15 percent [<a href="#rid12">12</a>]. In addition, isolates that appear susceptible to clindamycin and are resistant to <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> by standard susceptibility testing techniques may be capable of inducing resistance to clindamycin in the presence of the drug [<a href="#rid24">24</a>]. Clinicians should confer with the microbiology laboratory regarding evaluation of such isolates for inducible clindamycin resistance with D testing prior to treatment with clindamycin [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/z/d/html/467.html" rel="external">"Overview of antibacterial susceptibility testing", section on 'Inducible clindamycin resistance testing'</a>.)</p><p>Fluoroquinolones should not be used for treatment of skin and soft tissue infections due to MRSA; resistance may develop during therapy [<a href="#rid18">18,27</a>]. </p><p class="headingAnchor" id="H5"><span class="h2">Parenteral antibiotic therapy</span><span class="headingEndMark"> — </span>Treatment with parenteral antibiotic therapy is warranted in the following circumstances [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Extensive soft tissue involvement</p><p class="bulletIndent1"><span class="glyph">●</span>Signs of systemic toxicity</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid progression of clinical manifestations</p><p class="bulletIndent1"><span class="glyph">●</span>Persistence or progression of symptoms after 48 to 72 hours of oral therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromise</p><p class="bulletIndent1"><span class="glyph">●</span>Proximity of soft tissue infection to an indwelling device (such as a prosthetic joint or a vascular graft); soft tissue infection should be considered a manifestation of device infection if it originates on the skin directly overlying the prosthesis site</p><p></p><p>Treatment of bacteremia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p class="headingAnchor" id="H3994356405"><span class="h3">Antibiotics of choice</span><span class="headingEndMark"> — </span>Parenteral agents of choice for treatment of skin and soft tissue infection when MRSA is known or suspected include <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>. In areas where teicoplanin is available, some use it as the drug of choice for initial therapy of gram-positive pathogens, while others favor its use for patients with intolerance to vancomycin [<a href="#rid28">28</a>]. Alternative agents are discussed below. (See <a class="local">'Alternative agents'</a> below.)</p><p><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> is the antibiotic agent for which there is the greatest cumulative clinical experience for treatment of skin and soft tissue infection caused by MRSA [<a href="#rid4">4,29</a>]. <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is an acceptable alternate to vancomycin that does not require monitoring of drug levels [<a href="#rid30">30,31</a>]. Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef110072" data-inline-graphics="110072" href="/z/d/graphic/110072.html" rel="external">table 3</a>).</p><p>Patients with <em>S. aureus</em> infection due to an isolate with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> minimum inhibitory concentration (MIC) at the high end of the susceptible range (≥2 mcg/mL) may not respond to therapy as well as those with infection due to an isolate with a lower MIC [<a href="#rid32">32</a>]. In such cases, poor clinical response to vancomycin therapy should prompt use of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> or another agent. (See  <a class="medical medical_review" href="/z/d/html/3165.html" rel="external">"Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin"</a>.)</p><p>Issues related to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia", section on 'Preferred agents'</a>.)</p><p class="headingAnchor" id="H4176512818"><span class="h3">Alternative agents</span><span class="headingEndMark"> — </span>The choice of alternative agents with activity against MRSA may be based on logistics of administration, side-effect profiles, availability, cost, and known antibiotic susceptibility  (<a class="graphic graphic_table graphicRef110072" href="/z/d/graphic/110072.html" rel="external">table 3</a>). All of the alternative agents have been shown to be comparable to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for treatment of MRSA skin and soft tissue infections [<a href="#rid33">33-39</a>]; however, data comparing the alternative agents are limited.</p><p><a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> and <a class="drug drug_general" data-topicid="9515" href="/z/d/drug information/9515.html" rel="external">quinupristin-dalfopristin</a> should not be used for treatment of skin and soft tissue infections due to MRSA; their use is limited by adverse effects.</p><p class="headingAnchor" id="H2370258452"><span class="h4">Short-acting agents (parenteral or oral dosing)</span><span class="headingEndMark"> — </span>Short-acting agents with parenteral or oral dosing include oxazolidinones (<a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> and <a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">tedizolid</a>), the fluoroquinolone <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">delafloxacin</a>, and the <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a>; these agents may be used in the inpatient setting (with parenteral dosing) or outpatient setting (with oral dosing).</p><p class="headingAnchor" id="H4262615191"><span class="h5">Linezolid and tedizolid</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> and <a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">tedizolid</a> are oxazolidinones; both have bacteriostatic activity against MRSA and streptococci. Use of these drugs is limited by cost and toxicity (tedizolid may have less toxicity than linezolid); they should be reserved for patients who do not respond to or cannot tolerate other agents. In some centers, drug levels of linezolid are available and allow dosage adjustments that may limit the drug's toxicity. (See  <a class="medical medical_review" href="/z/d/html/129184.html" rel="external">"Linezolid and tedizolid (oxazolidinones): An overview"</a>.)</p><p><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> and <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> have been observed to have equivalent clinical cure rates overall for treatment of MRSA infection [<a href="#rid33">33,40</a>]. One systematic review including 3144 patients with skin and soft tissue infections noted linezolid appears to be at least as effective as vancomycin [<a href="#rid40">40</a>]. Linezolid has been shown to be as effective as vancomycin for the treatment of skin and soft tissue infection [<a href="#rid33">33,41-44</a>].</p><p><a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">Tedizolid</a> has been shown to be non-inferior to <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> for treatment of skin and soft tissue infection [<a href="#rid45">45-47</a>].</p><p>Issues related to <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p class="headingAnchor" id="H784004812"><span class="h5">Delafloxacin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">Delafloxacin</a> is a fluoroquinolone approved in June 2017 by the US Food and Drug Administration (FDA) for treatment of bacterial skin and soft tissue infections [<a href="#rid48">48-50</a>]. Delafloxacin has activity against staphylococci, including methicillin-resistant strains. It also has activity against gram-negative bacteria (including <em>Pseudomonas aeruginosa</em> and Enterobacteriaceae) as well as some anaerobes including <em>Clostridioides</em> <em>difficile</em>; it does not have activity against enterococci [<a href="#rid51">51</a>].</p><p><a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">Delafloxacin</a> susceptibility should be confirmed prior to use of delafloxacin; resistance among MRSA isolates has been reported [<a href="#rid52">52</a>]. </p><p>Efficacy data for <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">delafloxacin</a> include a randomized trial of 850 adults with skin and soft tissue infection treated with delafloxacin or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>; objective response at 48 to 72 hours was comparable between the groups (83 versus 80 percent), and the frequency of adverse events between the groups was similar [<a href="#rid53">53</a>]. The manufacturer reported that the drug was statistically noninferior to the combination of vancomycin and aztreonam at the endpoint of early clinical response at 48 to 72 hours in two phase III clinical trials and that the drug was well-tolerated [<a href="#rid53">53-56</a>].</p><p class="headingAnchor" id="H12885881"><span class="h5">Omadacycline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">Omadacycline</a> is a <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> approved in October 2018 by the FDA for treatment of bacterial skin and soft tissue infections. It has activity against <em>S.</em> <em>aureus</em> (methicillin-susceptible and -resistant isolates), <em>Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus</em> group (includes <em>S. anginosus</em>, <em>S. intermedius</em>, and <em>S. constellatus</em>), <em>Enterococcus faecalis, Enterobacter cloacae</em>, and <em>Klebsiella pneumoniae</em>.</p><p>In a randomized trial including more than 600 patients with skin and soft tissue infections treated with <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a> or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> (intravenous [IV] therapy with transition to oral therapy allowed after three days; total duration 7 to 14 days), the clinical response (at least 20 percent reduction in lesion size after 48 to 72 hours of therapy) was comparable between the groups (85 percent) [<a href="#rid57">57</a>]. The drugs had a similar safety profile, and the efficacy of omadacycline was similar for methicillin-susceptible and methicillin-resistant <em>S. aureus</em> infections.</p><p class="headingAnchor" id="H1956049210"><span class="h4">Short-acting parenteral agents</span><span class="headingEndMark"> — </span>Short-acting parenteral agents include <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> and <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">ceftobiprole</a> (dosed twice daily); use of these agents requires inpatient management.</p><p class="headingAnchor" id="H1544552072"><span class="h5">Ceftaroline (and ceftobiprole)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">Ceftaroline</a> and <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">ceftobiprole</a> are fifth-generation cephalosporins with broad-spectrum activity against gram-positive and gram-negative organisms. Ceftaroline has activity against MRSA and staphylococci with reduced susceptibility to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>, or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> as well as gram-negative pathogens [<a href="#rid58">58,59</a>]. Ceftobiprole has activity against MRSA, penicillin-resistant <em>Streptococcus pneumoniae</em>, enterococci, and Enterobacteriaceae [<a href="#rid60">60,61</a>].</p><p>For treatment of complicated skin and skin structure infection, <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> has been found to be non-inferior to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> [<a href="#rid36">36</a>], and <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">ceftobiprole</a> has been observed to be as effective as vancomycin (with or without <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>) [<a href="#rid39">39,62</a>].</p><p><a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">Ceftobiprole</a> is not available in the United States but is available in Canada and Europe.</p><p class="headingAnchor" id="H1890837400"><span class="h5">Iclaprim</span><span class="headingEndMark"> — </span>Iclaprim is a parenteral agent with bactericidal activity against gram-positive bacteria including MRSA. It is an inhibitor of the enzyme dihydrofolate reductase, blocking a key step in thymidine synthesis [<a href="#rid63">63</a>]. In randomized trials, it has been observed to be noninferior to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for treatment of skin and soft tissue infections [<a href="#rid63">63,64</a>]. It is not yet available for use in the United States.</p><p class="headingAnchor" id="H2986428080"><span class="h4">Long-acting parenteral agents</span><span class="headingEndMark"> — </span>Long-acting parenteral agents include <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">dalbavancin</a>, <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">oritavancin</a>, and <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a>. Dalbavancin has a half-life of 14 days and oritavancin has a half-life of 10 days. These agents are administered as a single dose, which may be useful for patients who warrant parenteral therapy but do not otherwise require inpatient management. Telavancin is dosed once daily.</p><p class="headingAnchor" id="H2004079689"><span class="h5">Dalbavancin, oritavancin, and telavancin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">Dalbavancin</a>, <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">oritavancin</a>, and <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a> are lipoglycopeptides that inhibit cell wall synthesis and disrupt cell membrane permeability; they have bactericidal activity against MRSA and other gram-positive organisms [<a href="#rid65">65-67</a>].</p><p><a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">Dalbavancin</a> and <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">oritavancin</a> are long-acting agents; these agents may be useful for patients who warrant parenteral therapy but do not otherwise require inpatient management and may simplify adherence [<a href="#rid68">68</a>].</p><p><a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">Dalbavancin</a> has been demonstrated to be non-inferior to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> followed by oral <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> for treatment of skin and soft tissue infection in two studies including more than 1200 patients [<a href="#rid37">37</a>]. We favor administration as a single dose (1500 mg IV); this approach was shown to be noninferior to a two-dose regimen (1000 mg IV followed by 500 mg IV one week later) in a randomized trial including 698 patients with acute bacterial skin and skin structure infection treated with the single-dose or two-dose regimen; favorable clinical outcome (≥20 percent reduction in the area of erythema at 48 to 72 hours) was observed in 81.4 versus 84.2 percent, respectively (difference -2.9 percent, 95% CI -8.5 to 2.8 percent) [<a href="#rid68">68</a>]. Adverse effects associated with dalbavancin include gastrointestinal intolerance (nausea, diarrhea, constipation), transaminitis, hypokalemia, and hypotension. </p><p><a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">Oritavancin</a> has been demonstrated to be non-inferior to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for treatment of skin and soft tissue infection in randomized trials including nearly 1000 patients [<a href="#rid34">34,38,69</a>]. Oritavancin may artificially prolong activated partial thromboplastin time (aPTT) for up to 5 days, prolong prothrombin time (PT) and international normalized ratio (INR) for up to 12 hours, and prolong activated whole blood clotting time (ACT) for up to 24 hours [<a href="#rid70">70</a>]. For patients who require aPTT monitoring 5 days of oritavancin administration, a non-phospholipid dependent coagulation test (such as a Factor Xa assay) may be used; alternatively, an anticoagulant not requiring aPTT may be used. Other adverse effects of oritavancin include nausea, vomiting, and headache.</p><p><a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">Telavancin</a> has been demonstrated to be at least as effective as <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for treatment of skin and soft tissue infection in several trials [<a href="#rid35">35,71,72</a>]. Adverse effects of telavancin include taste disturbance, nausea, vomiting, and renal dysfunction.</p><p class="headingAnchor" id="H112639561"><span class="h1">DURATION OF THERAPY</span><span class="headingEndMark"> — </span>The appropriate duration of therapy for treatment of skin and soft tissue infection depends on the nature of the clinical presentation, and the clinical response should guide duration of therapy.</p><p>Patients with mild infection who warrant outpatient management with oral antibiotic therapy should have repeat evaluation after 24 to 48 hours to verify that there is a clinical response [<a href="#rid3">3</a>]. Patients with MRSA responsive to oral therapy are typically treated for 5 days; extension of the duration (up to 14 days) may be warranted in the setting of severe infection and/or slow response to therapy. Lack of response may be due to infection with resistant organism(s), inadequate adherence or source control, or presence of a deeper, more serious infection than previously realized.</p><p>Patients with infection warranting parenteral therapy (in the absence of bacteremia or involvement beyond soft tissue) are typically treated for a total duration of 5 to 14 days. Once there are signs of clinical improvement with no evidence of systemic toxicity, antibiotics may be transitioned from parenteral to oral therapy  (<a class="graphic graphic_table graphicRef64178" href="/z/d/graphic/64178.html" rel="external">table 2</a>).</p><p>The management of patients with bacteremia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p class="headingAnchor" id="H6873619"><span class="h1">RECURRENT INFECTION</span><span class="headingEndMark"> — </span>Recurrent MRSA infection is common. In one study, infections recurred in 51 percent of subjects by six months [<a href="#rid73">73</a>].</p><p>The initial clinical approach to patients with recurrent skin and soft tissue infection when MRSA is known or suspected is the same as for patients with a first episode. Patients should be evaluated and treated for underlying conditions that may predispose to infection. (See <a class="local">'Clinical approach'</a> above.)</p><p>Antibiotic selection should be guided by careful review of prior and current culture and susceptibility data (see <a class="local">'Antibiotic selection'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with hemodynamic instability and a prior MRSA isolate with a <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> minimum inhibitory concentration at the high end of the susceptible range (≥2 mcg/mL), empiric treatment should consist of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> or <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> (or in combination) rather than vancomycin [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are clinically stable, the choice between whether to treat empirically with an antibiotic agent used previously and a different agent should be guided by individual clinical circumstances (such as allergy history and concomitant medications).</p><p></p><p>Antibiotic therapy should be tailored to culture and susceptibility data when available.</p><p>The duration of therapy for recurrent infection is the same as for an initial episode. (See <a class="local">'Duration of therapy'</a> above.)</p><p>Issues related to the prevention of MRSA infection and decolonization strategies are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control"</a>.)</p><p class="headingAnchor" id="H4042067568"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110086.html" rel="external">"Society guideline links: Skin and soft tissue infections"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110550.html" rel="external">"Society guideline links: Management of <i>Staphylococcus aureus</i> infection"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15481.html" rel="external">"Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4025.html" rel="external">"Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> – Patients with skin and soft tissue infections known or suspected to be due to methicillin-resistant <em>Staphylococcus aureus </em>(MRSA) may present with cellulitis, abscess, or both. Patients with cellulitis should be managed with antibiotic therapy. Patients with abscess should undergo incision and drainage and warrant antibiotic therapy in most circumstances as discussed separately. (See <a class="local">'Clinical approach'</a> above and  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric treatment of MRSA</strong> – Empiric coverage for MRSA is often warranted, particularly for patients with systemic toxicity, purulent drainage, abscess, an immunocompromising condition, or other risk factors for MRSA  (<a class="graphic graphic_table graphicRef53504" href="/z/d/graphic/53504.html" rel="external">table 1</a>). Antibiotic therapy should be tailored to culture and susceptibility data when available. (See <a class="local">'Antibiotic selection'</a> above and  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral antibiotics</strong> – Patients with mild infection (localized involvement with no systemic symptoms) may be treated with oral antibiotic therapy. Oral antibiotic agents of choice include <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, tetracyclines (such as <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>), and <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>; dosing is summarized in the table  (<a class="graphic graphic_table graphicRef64178" href="/z/d/graphic/64178.html" rel="external">table 2</a>). In general, the choice between these agents is guided by individual clinical circumstances. (See <a class="local">'Oral antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for parenteral antibiotics</strong> – Patients with the following factors warrant parenteral therapy (see <a class="local">'Parenteral antibiotic therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extensive soft tissue involvement</p><p class="bulletIndent2"><span class="glyph">•</span>Signs of systemic toxicity</p><p class="bulletIndent2"><span class="glyph">•</span>Rapid progression of clinical manifestations</p><p class="bulletIndent2"><span class="glyph">•</span>Persistence or progression of symptoms after 48 to 72 hours of oral therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Immunocompromise</p><p class="bulletIndent2"><span class="glyph">•</span>Proximity of soft tissue infection to an indwelling device (such as a prosthetic joint or a vascular graft); soft tissue infection should be considered a manifestation of device infection if it originates on the skin directly overlying the prosthesis site</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral antibiotics</strong> – Parenteral agents of choice for treatment of skin and soft tissue infection when MRSA is known or suspected include <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>  (<a class="graphic graphic_table graphicRef110072" href="/z/d/graphic/110072.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> is not an option, alternative parenteral agents are available for treatment of skin and soft tissue infection when MRSA is known or suspected; the optimal approach to choosing between these agents is uncertain. Pending further study, the choice may be based on logistics of administration, side-effect profiles, availability, antimicrobial susceptibility testing results, and cost  (<a class="graphic graphic_table graphicRef110072" href="/z/d/graphic/110072.html" rel="external">table 3</a>) (see <a class="local">'Alternative agents'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Short-acting agents with parenteral or oral formulations</strong> – These include <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">tedizolid</a>, <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">delafloxacin</a>, and <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a>; these agents may be used in the inpatient setting (with parenteral dosing) or outpatient setting (with oral dosing).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Short-acting parenteral agents with no oral formulation</strong> – These include <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> and <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">ceftobiprole</a> (where available); use of these agents requires inpatient management.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Long-acting parenteral agents</strong> – These include <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">dalbavancin</a>, <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">oritavancin</a>, and <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a>. Dalbavancin has a half-life of 14 days, and oritavancin has a half-life of 10 days; these agents may be useful for patients who warrant parenteral therapy but do not otherwise require inpatient management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – The duration of therapy for treatment of skin and soft tissue infection due to MRSA depends on the nature of the clinical presentation and should be guided by clinical response. Patients with skin or soft tissue infection responsive to oral therapy are typically treated for 5 days; extension of the duration (up to 14 days) may be warranted in the setting of severe infection and/or slow response to therapy. Patients with infection warranting parenteral therapy (in the absence of bacteremia or involvement beyond soft tissue) are typically treated for a total duration of 5 to 14 days. Once there are signs of clinical improvement with no evidence of systemic toxicity, parenteral antibiotics may be transitioned to oral therapy. (See <a class="local">'Duration of therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA 2013.</li><li class="breakAll">European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1, 2018. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.1_Breakpoint_Tables.pdf (Accessed on August 09, 2018).</li><li><a class="nounderline abstract_t">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Singer AJ, Talan DA. Management of skin abscesses in the era of methicillin-resistant Staphylococcus aureus. N Engl J Med 2014; 370:1039.</a></li><li><a class="nounderline abstract_t">Fitch MT, Manthey DE, McGinnis HD, et al. Videos in clinical medicine. Abscess incision and drainage. N Engl J Med 2007; 357:e20.</a></li><li><a class="nounderline abstract_t">Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007; 44:483.</a></li><li><a class="nounderline abstract_t">Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471.</a></li><li><a class="nounderline abstract_t">Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178.</a></li><li><a class="nounderline abstract_t">Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004; 39:47.</a></li><li><a class="nounderline abstract_t">Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007; 44:777.</a></li><li><a class="nounderline abstract_t">Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007; 357:380.</a></li><li><a class="nounderline abstract_t">Drugs for MRSA skin and soft-tissue infections. Med Lett Drugs Ther 2014; 56:39.</a></li><li><a class="nounderline abstract_t">Talan DA, Lovecchio F, Abrahamian FM, et al. A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection. Clin Infect Dis 2016; 62:1505.</a></li><li><a class="nounderline abstract_t">Moellering RC Jr. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46:1032.</a></li><li><a class="nounderline abstract_t">Daum RS, Miller LG, Immergluck L, et al. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. N Engl J Med 2017; 376:2545.</a></li><li><a class="nounderline abstract_t">Miller LG, Daum RS, Creech CB, et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med 2015; 372:1093.</a></li><li><a class="nounderline abstract_t">Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666.</a></li><li><a class="nounderline abstract_t">Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007; 51:423.</a></li><li><a class="nounderline abstract_t">Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004; 50:854.</a></li><li><a class="nounderline abstract_t">Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005; 40:1429.</a></li><li><a class="nounderline abstract_t">Bowen AC, Carapetis JR, Currie BJ, et al. Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. Open Forum Infect Dis 2017; 4:ofx232.</a></li><li><a class="nounderline abstract_t">Bowen AC, Lilliebridge RA, Tong SY, et al. Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole? J Clin Microbiol 2012; 50:4067.</a></li><li><a class="nounderline abstract_t">Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257.</a></li><li><a class="nounderline abstract_t">Panagea S, Perry JD, Gould FK. Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 1999; 44:581.</a></li><li><a class="nounderline abstract_t">Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530.</a></li><li><a class="nounderline abstract_t">Trucksis M, Hooper DC, Wolfson JS. Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med 1991; 114:424.</a></li><li><a class="nounderline abstract_t">Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010; :CD007022.</a></li><li><a class="nounderline abstract_t">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e10.</a></li><li><a class="nounderline abstract_t">Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673.</a></li><li><a class="nounderline abstract_t">Syriopoulou V, Dailiana Z, Dmitriy N, et al. Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents. Pediatr Infect Dis J 2016; 35:511.</a></li><li><a class="nounderline abstract_t">Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.</a></li><li><a class="nounderline abstract_t">Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481.</a></li><li><a class="nounderline abstract_t">Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 2015; 60:254.</a></li><li><a class="nounderline abstract_t">Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46:1683.</a></li><li><a class="nounderline abstract_t">Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641.</a></li><li><a class="nounderline abstract_t">Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370:2169.</a></li><li><a class="nounderline abstract_t">Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014; 370:2180.</a></li><li><a class="nounderline abstract_t">Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008; 52:37.</a></li><li><a class="nounderline abstract_t">Yue J, Dong BR, Yang M, et al. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2016; :CD008056.</a></li><li><a class="nounderline abstract_t">Yue J, Dong BR, Yang M, et al. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2013; :CD008056.</a></li><li><a class="nounderline abstract_t">Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260.</a></li><li><a class="nounderline abstract_t">Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445.</a></li><li><a class="nounderline abstract_t">Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789.</a></li><li><a class="nounderline abstract_t">Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013; 309:559.</a></li><li><a class="nounderline abstract_t">Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014; 14:696.</a></li><li><a class="nounderline abstract_t">Burdette SD, Trotman R. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. Clin Infect Dis 2015; 61:1315.</a></li><li><a class="nounderline abstract_t">Candel FJ, Peñuelas M. Delafloxacin: design, development and potential place in therapy. Drug Des Devel Ther 2017; 11:881.</a></li><li class="breakAll">The Medical Letter. Delafloxacin (Baxdela) - A new fluorquinolone antibiotic. https://secure.medicalletter.org/article-share?a=1543a&amp;p=tml&amp;title=Delafloxacin%20(Baxdela)%20-%20A%20New%20Fluoroquinolone%20Antibiotic&amp;cannotaccesstitle=1 (Accessed on March 22, 2018).</li><li><a class="nounderline abstract_t">Saravolatz LD, Stein GE. Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone. Clin Infect Dis 2019; 68:1058.</a></li><li><a class="nounderline abstract_t">Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol 2015; 10:1111.</a></li><li><a class="nounderline abstract_t">Iregui A, Khan Z, Malik S, et al. Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, New York. Clin Infect Dis 2020; 70:1758.</a></li><li><a class="nounderline abstract_t">O'Riordan W, McManus A, Teras J, et al. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study. Clin Infect Dis 2018; 67:657.</a></li><li class="breakAll">Cammarata S, Gardovskis J, Farley B, et al. Results of a global phase 3 study of delafloxacin (DLX) compared to vancomycin with aztreonam (VAN) in acute bacterial skin and skin structure infections (ABSSSI). Melinta Therapeutics, ID Week 2015. http://melinta.com/wp-content/uploads/2016/03/IDWeek2015-complete_302_ABSSSI_study_results.pdf (Accessed on June 29, 2017).</li><li class="breakAll">O'Riordan W, McManus A, Teras J, et al. A global phase 3 study of delafloxacin (DLX) compared to vancomycin/aztreonam (VAN/AZ) in patients with acute bacterial skin and skin structure infections (ABSSSI). ID Week 2016. http://melinta.com/wp-content/uploads/2016/10/IDWEEK-1347-Baxdela-vs-VAN-AZ-302-Ph3-Results.pdf (Accessed on June 29, 2017).</li><li><a class="nounderline abstract_t">Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother 2017; 72:3471.</a></li><li><a class="nounderline abstract_t">O'Riordan W, Green S, Overcash JS, et al. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. N Engl J Med 2019; 380:528.</a></li><li><a class="nounderline abstract_t">Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011; 52:1156.</a></li><li><a class="nounderline abstract_t">Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob Agents Chemother 2013; 57:3178.</a></li><li><a class="nounderline abstract_t">Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007; 16:419.</a></li><li><a class="nounderline abstract_t">Willems RJ, Top J, van Santen M, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11:821.</a></li><li><a class="nounderline abstract_t">Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46:647.</a></li><li><a class="nounderline abstract_t">Huang DB, O'Riordan W, Overcash JS, et al. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1. Clin Infect Dis 2018; 66:1222.</a></li><li><a class="nounderline abstract_t">Holland TL, O'Riordan W, McManus A, et al. A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Karlowsky JA, Nichol K, Zhanel GG. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clin Infect Dis 2015; 61 Suppl 2:S58.</a></li><li><a class="nounderline abstract_t">Billeter M, Zervos MJ, Chen AY, et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008; 46:577.</a></li><li><a class="nounderline abstract_t">Saravolatz LD, Stein GE. Oritavancin: A Long-Half-Life Lipoglycopeptide. Clin Infect Dis 2015; 61:627.</a></li><li><a class="nounderline abstract_t">Dunne MW, Puttagunta S, Giordano P, et al. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. Clin Infect Dis 2016; 62:545.</a></li><li><a class="nounderline abstract_t">Lodise TP, Redell M, Armstrong SO, et al. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials. Open Forum Infect Dis 2017; 4:ofw274.</a></li><li class="breakAll">ORBACTIV (oritavancin) for injection, for intravenous use. FDA package insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206334s002lbl.pdf (Accessed on February 02, 2016).</li><li><a class="nounderline abstract_t">Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40:1601.</a></li><li><a class="nounderline abstract_t">Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50:862.</a></li><li><a class="nounderline abstract_t">Miller LG, Eells SJ, David MZ, et al. Staphylococcus aureus skin infection recurrences among household members: an examination of host, behavioral, and pathogen-level predictors. Clin Infect Dis 2015; 60:753.</a></li><li><a class="nounderline abstract_t">Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53:158.</a></li></ol></div><div id="topicVersionRevision">Topic 3176 Version 71.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.1_Breakpoint_Tables.pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1, 2018. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.1_Breakpoint_Tables.pdf (Accessed on August 09, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947530" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24620867" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of skin abscesses in the era of methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17989377" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Videos in clinical medicine. Abscess incision and drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243049" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243048" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11294701" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The changing epidemiology of Staphylococcus aureus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15206052" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Origins of community strains of methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17304447" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17652653" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24818839" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Drugs for MRSA skin and soft-tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27025829" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444820" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657870" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25785967" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914702" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Methicillin-resistant S. aureus infections among patients in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116664" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15153884" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15844065" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29255730" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23052313" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557972" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588329" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12182377" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992885" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Emerging resistance to fluoroquinolones in staphylococci: an alert.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20556772" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Teicoplanin versus vancomycin for proven or suspected infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24973422" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15227611" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26849158" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184410" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015695" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25294250" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444791" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20695801" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24897082" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Once-weekly dalbavancin versus daily conventional therapy for skin infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24897083" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Single-dose oritavancin in the treatment of acute bacterial skin infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954698" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26758498" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Linezolid versus vancomycin for skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846850" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Linezolid versus vancomycin for skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917519" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814880" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14605050" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23403680" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24909499" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26105167" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28356714" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Delafloxacin: design, development and potential place in therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28356714" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Delafloxacin: design, development and potential place in therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30060092" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26119479" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31412357" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, New York.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29518178" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29518178" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29518178" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029278" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30726689" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21467022" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23629712" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17371191" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963275" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18225981" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29281036" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29530858" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316559" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199045" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25900171" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Oritavancin: A Long-Half-Life Lipoglycopeptide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26611777" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480266" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480266" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15889357" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495243" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25428411" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Staphylococcus aureus skin infection recurrences among household members: an examination of host, behavioral, and pathogen-level predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690622" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
